Learnings From a Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of A Novel Therapeutic in Locally Advanced/Metastatic HER2- Expressing Solid Tumors
Time: 11:00 am
day: Conference Day Two
Details:
For full session details, download the full event guide
